Did you compare the blended data with the SOC? That is the starting point. You will see the DCVax-L blended blinded result would beat SOC by a wide margin. When the data is unblinded, I believe the treatment data would beat the SOC even more. Why it takes so long? Because they want to prove to the regulators that the data is an actual data from real survivors. That takes time. Regulators are smart, they would value facts more than just prediction. When this actual data turns out as longs here expected to be so good, the FDA and UK, Germany and Canada regulators would be so happy to approve it, I believe, because it is undeniable. Of course we will see how it turns out. But I am glad I got the glimpse of interim blended data that keeps improving. So that is my opinion.
News 
Market Data 
Discover 
